Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral GLP-1 candidate will soon report key phase 3 results in weight management.
It has now been more than three years since the U.S. Food and Drug Administration (FDA) first approved tirzepatide, the medicine Eli Lilly markets as Mounjaro for treating diabetes and as Zepbound for ...
Prosper Junior Bakiny is a contributing Motley Fool healthcare analyst covering biotechnology, pharmaceuticals, and healthcare stocks. Before The Motley Fool, Prosper wrote about investing topics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback